That is THE question. There is no doubt that vaccination is the golden example of public health policy at its best. And there is also no doubt that vaccination cost-effectively improves health and prevents disability and death; vaccinations to prevent COVID-19 being the most recent example. Unfortunately, policy decisions to adopt vaccines and/or enlarge programs are made primarily, and often exclusively, on cost analyses and projections; nonetheless, current cost models are insufficient to correctly attribute value to vaccines. No one factor, especially cost, should determine vaccination availability.

This paper, authored by Policy Wisdom’s President and CEO, Ana Rita Gonzalez, examines the challenges to increase access to vaccines, issues with cost analysis that must be considered, and provides recommendations on overcoming the cost barriers, to put into the right perspective the need of vaccination access.  

Edit 2023: Because a comprehensive vaccine value and impact analysis can show that effective vaccines outweigh their costs in benefits such as a better-educated and a more productive population, smaller family sizes, and overall economic growth. Such results will inevitably encourage policy makers to improve immunization programs by increasing health budgets and allowing for the increase in the number and types of vaccines available. This is a benefit not only for the vaccines we already know, but for the ones that we might need in the future after the COVID “unexpected” pandemic, since we don’t know when a new pandemic may be around the corner.